Note: Ingredients listed on restricted chemical lists
EC/CAS
203-473-3/107-21-1
Name of the chemical
Ethane-1,2-diol
Concentration
≥70
General Information
Version
1.0
Revision date
2023-11-16
Product name
Ultralife 4
1.2.1 Relevant identified uses
Industrial use,Professional use
supplier name
Morris Lubricants
Emergency telephone
+44 (0) 1743 232200
Icons in SDS
Company Information
company name
Morris Lubricants
e-mail address of the competent person responsible for the Safety Data Sheet
sds@morris-lubricants.co.uk
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H302, H360D, H373
Hazard statements
Code
Statements
H302
Harmful if swallowed
Section 2
SECTION 2: Hazards identification
Adverse physicochemical, human health and environmental effects
No additional information available
2.2 Label elements
Labelling
Hazard pictograms
GHS07 GHS08
Signal word
Danger
Contains
ethanediol; 2-Ethylhexanoic acid, Sodium salt
Hazard statements
H302 - Harmful if swallowed. H360D - May damage the unborn child. H373 - May cause damage to organs (kidneys) through prolonged or repeated exposure (oral).
Precautionary statements
P201 - Obtain special instructions before use. P260 - Do not breathe mist, spray, vapours. P264 - Wash hands thoroughly after handling. P280 - Wear protective clothing, eye protection, face protection. P301+P312 - IF SWALLOWED: Call a POISON CENTER, doctor if you feel unwell. P308+P313 - IF exposed or concerned: Get medical advice/attention. P501 - Dispose of contents and container to hazardous or special waste collection point, in accordance with local, regional, national and/or international regulation.
Additional information
Restricted to professional users.
PBT Substances
not relevant – no registration required
vPvB Substances
not relevant – no registration required Contains no PBT and/or vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %
